Axiller lenf nodu pozitif meme kanserinde non-sentinel lenf nodu pozitifliğine etki eden faktörler ve nomogramların etkinliğinin karşılaştırılması
Amaç: Amacımız aksiller lenf nodu pozitif meme kanserinde nonsentinel lenf nodu (NSLN) pozitifliğine etki eden faktörleri araştırmak ve hasta grubumuzda Memorial Sloan-Kettering Cancer Center (MSKCC) ve Stanford nomogramlarının etkinliğini karşılaştırmaktır. Yöntemler: 01.01.2008 - 31.08.2011 tarihleri arasında Ondokuz Mayıs Üniversitesi Tıp Fakültesi Genel Cerrahi Kliniği’nde sentinel lenf nodu biyopsisi (SLNB) sonucunda sentinel lenf nodunda metastaz saptanan invaziv meme kanseri olan 112 hasta çalışmaya alındı. Karşılaştırılacak değişkenler SPSS 15.0 versiyonu programından yararlanılarak kaydedildi. Lojistik regresyon analizi ile NSLN pozitifliğine etki eden risk faktörleri araştırıldı. P< 0.05 anlamlılık düzeyi olarak kabul edildi. Her iki nomogram icin “Receiver Operating Characteristics (ROC)” eğrileri oluşturuldu ve eğriler altındaki alanlar(AUC) hesaplandı. AUC değeri 0.70 ve üzerinde hesaplanan yöntem etkin olarak kabul edildi. Bulgular: Tek değişkenli analizde tümör boyutu, multifokalite, lenfovasküler invazyon varlığı, SLN’daki metastazın makrometastaz oluşu, SLN’da kapsül dışı invazyon varlığı ve metastatik SLN sayısının toplam SLN sayısına oranı anlamlı bulundu. Çok değişkenli analizde lenfovasküler invazyon, SLN’da kapsül dışı invazyon ve metastatik SLN sayısının toplam SLN sayısına oranı NSLN metastazı ile ilgili bağımsız prediktif faktörler olarak saptandı. MSKCC ve Stanford nomogramlarının ikisinin de hasta grubumuzda etkin olmakla birlikte MSKCC nomogramının daha etkin olduğu sonucuna vardık. Sonuç: Nomogramlar aksillada NSLN’unda metastataz olasılığı hakkında yol gösterici yöntemlerdir. Ancak henüz aksiller lenf nodu diseksiyonunun (ALND) yerini alacak kapasitede değildirler. NSLN pozitifliğine etki eden yeni prediktif faktörlerin ortaya konulması ile etkinlikleri artırılabilir. Her klinik kendisine en uygun nomogramı belirlemeli ve kullanmalı veya kendi nomogramını oluşturmalıdır.
Comparison of factors affecting non-sentinel lymph node positivity and nomogram efficacy in axillary lymph node positive breast cancer
Objective: Our aim is to investigate the factors that affect non-sentinel lymph node positivity in patients with axillary lymph node positive breast cancer and to evaluate the effectiveness of Memorial Sloan-Kettering Cancer Center (MSKCC) and Stanford nomograms in our patients group. Methods: One hundred and twelve invasive breast cancer patients with metastatic sentinel lymph node biopsy (SLNB) who underwent surgery, between January 2008 and August 2011, in Department of General Surgery at Ondokuz Mayıs University School of Medicine were included in the study. Variables that will be compared with were recorded by using SPSS 15.0 version. Risk factors which effect the non sentinel lymph node positivity were analysed by logistic regression analysis. P < 0.05 was considered as significant. Receiver operating characteristics (ROC) curves for nomograms were created and area under curves (AUC) were computed. AUC values equal to or greater than 0.70 have been accepted as good discrimination for prediction of non-sentinel lymph node metastasis. Results: In univariate analysis, tumor size, presence of multifocality, lenfovascular invasion, metastatic sentinel lymph node with macrometastasis and extracapsular invasion, the ratio of number of metastatic sentinel lymph node to total number of sentinel lymph node were found to be significant. In multivariate analysis, presence of lenfovascular invasion, extracapsul invasion and the ratio of number of metastatic sentinel lymph node to total number of sentinel lymph node were found to be independent factors for metastatic non-sentinel lymph node. For our patients group we conluded that the both of MSKCC and Stanford nomograms were effective. Conclusion: Nomograms are methods to predict the possibility of non sentinel lymphnode metastasis. But they have yet not the ability to replace axillary lymph node dissection. Their effectiveness can be increased by new predictive factors for non-sentinel lymph node positivity. Each clinic should determine and use most suitable nomogram or should create own nomogram.
___
- Baring CC, Squires TS, Tang T. Cancer Statistics 1993.
CA Cancer J Clin 1993; 43: 4-26.
- Silvenberg E, Lubera J, Cancer Statistics 1987, CA
Cancer J Clin 1987; 37: 19-24.
- Greenlee RT, Murray T, Bolden S, et al. Cancer
Statistics 2000. CA Cancer Clin 2000; 50: 7-33.
- Dees EC, Lawrence N, Souba WW, et al. Does
Information From Axillary Dissection Change
Treatment In Clinically Node-Negative Patients With
Breast Cancer. Ann Surg 1999; 226: 279-87.
- Anderson BO, Austin-Seymour M.M, Gralow JR, et al. A
Multidisciplinary Approach to Locoregional
Management of the Axilla for Primary Operable Breast
Cancer. Cancer Control 1997; 4: 491-9.
- Weaver DL, Krag DN, Ashikaga T, et al. Pathologic
Analysis of Sentinel and nonsentinel Lymph Nodes In
Breast Carcinoma: A Multicenter Study. Cancer 2000;
88: 1099-107.
- Barth R.J, Danforth DN, Venzon DJ, et al. Level of
Axillary Involvement by Lymph Node Metastases From
Breast Cancer is not An Independent Predictor of
Survival. Arch Surg 1991;126:574-77.
- Arthur Z, Krasnow H, Robert SH. Lymphocintigraphy
Revisted. Nucl Med Ann 1999; 76: 17-96.
- Krag DN. Minimal Access Surgery for Staging Regional
Lymph Nodes: The Sentinel Node Concept. Curr Probl
Surg 1998; 35: 951-18.
- Brenin DR, Morrow M, Moughan J, et al. Manegement
Of Axillary Lymph Node In Breast Cancer: A National
patterns of Care Study of 17,151 Patients. Ann Surg
1999; 230: 686-91.
- Veronesi U, Paganelli G,Viale G. A randomized
comparison of sentinel-node biopsy with routine
axillary dissection in breast cancer. N Eng J Med 2003;
349: 546-53.
- Van Zee KJ, Manasseh D, Bevilacqua J, et al. A
nomogram for predicting the likelihood of additional
nodal metastases in breast cancer patients with a
positive sentinel lymph node biopsy. Ann Surg Oncol
2003; 10: 1140–51.
- Gur AS, Unal B, Ozbek U, et al. Validation of breast
cancer nomograms for predicting the non-sentinel
lymph node metastases after a positive sentinel lymph
node biopsy in a multi-center study. Eur J Surg Oncol
2010; 36: 30-5.
- Kell MR, Burke JP, Barry M, et al. Outcome of axillary
staging in early breast cancer: a meta-analysis. Breast
Cancer Res Treat 2010; 120: 441-7.
- Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph
node biopsy in breast cancer: Ten-year results of a
randomized controlled study. Ann Surg 2010; 251: 595-
600.
- Lyman GH, Giuliano AE, Somerfield MR, et al.
American Society of Clinical Oncology. American
Society of Clinical Oncology guideline
recommendations for sentinel lymph node biopsy in
early-stage breast cancer. J Clin Oncol 2005; 23: 7703-
20.
- Chu KU, Turner RR, Hansen NM, et al. Do all patients
with sentinel node metastasis from breast carcinoma
need complete axillary node dissection? Ann Surg
1999; 229: 536-41.
- Weir L, Speers C, D’yachkova Y, et al. Prognostic
significance of the number of axillary lymph nodes
removed in patients with mode negative breast cancer.
J Clin Oncol 2002; 20: 1793–9.
- Fisher B, Montague E, Redmond C, et al. Comparison
of radical mastectomy with alternative treatments for
primary breast cancer. A first report of results from a
prospective randomized clinical trial. Cancer 1977; 39:
2827-39.
- Krag DN, Anderson SJ, Julian TB, et al. Sentinellymph-node
resection compare with conventional
axillary-lymph-node dissection in clinically nodenegative
patients with breast cancer: overall survival
findings from the NSABP B-32 randomised phase 3
trial. Lancet Oncol 2010; 11: 927-33.
- Early Breast Cancer Trialists' Collaborative Group
(EBCTCG). Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-
year survival: an overview of the randomised trials.
Lancet 2005; 365: 1687-717.
- Ozaslan C, Kuru B. Lymphedema after treatment of
breast cancer. Am J Surg 2004; 187: 69-72.
- Latosinsky S, Dabbs K, Moffat F. Canadian Association
of General Surgeons and American College of Surgeons
Evidence-Based Reviews in Surgery. 27. Quality-of-life
outcomes with sentinel node biopsy versus standard
axillary treatment in patients with operable breast
cancer. Randomized multicenter trial of sentinel node
biopsy versus standard axillary treatment in operable
breast cancer: the ALMANAC Trial. Can J Surg 2008; 51:
483-5.
- Travagli JP, Atallah D, Mathieu MC, et al. Sentinel
lymphadenectomy without systematic axillary
dissection in breast cancer patients: predictors of nonsentinel
lymph node metastasis Eur J Surg Oncol 2003;
29: 403-6.
- Sachdev U, Murphy K, Derzie A, et al. Predictors of
nonsentinel lymph node metastasis inbreast cancer
patients. Am J Surg 2002; 183: 213–7.
- Bolster MJ, Peer PGM, Bult P, et al. Risk factors for
non-sentinel lymph node metastases in patients with
breast cancer. The outcome of a multi-institutional
study. Ann Surg Oncol 2007; 14: 181-9.
- Schrenk P, Konstantiniuk P, Wölfl S. Prediction of
non-sentinel lymph node status in breast cancer with a
micrometastatic sentinel node. Br J Surg 2005; 92: 707-
13.
- Zhang T, Wang H, Chen B, et al. Risk factors for nonsentinel
lymph node metastases in breastcancer
patients with positive sentinel lymph nodes. Chinese
Med J 2008; 121: 2107-9.
- Kapur U, Rubinas T, Ghai R, et al. Prediction of
nonsentinel lymph node metastasis in sentinel nodepozitive
breast carcinoma. Ann of Diagn Pathol 2007;
11: 10-12.
- Stitzenberg KB, Meyer AA, Stern SL, et al.
Extracapsular extension of the sentinel lymph node
metasases: a prediction of nonsentinel node tumor
burden. Ann Surg 2003; 237: 607-12.
- Park J, Park KM, Park JM, et al. Predicting Factors of
Nonsentinel Lymph Node Metastasis in Breast Cancer
Patients with Sentinel Lymph Node Metastasis. J
Korean Surg Soc 2010; 79: 20-26.
- Reynolds C, Mick R, Donohue JH et al. Sentinel lymph
node biopsy with metastasis: can axillary dissection be
avoided in some patients with breast cancer? J Clin
Oncol 1999; 17: 1720-6.
- Van Iterson V, Leidenius M. Krogerus L, et al.
Predictive factors for the status of non-sentinel nodes
in breast cancer patients with tumor positive sentinel
nodes. Breast Cancer Research and Treatment 2003;
82: 39-45.
- Mignotte H, Treilleux I, Faure C, et al. Axillary lymphnode
dissection for positive sentinel nodes in breast
cancer patients. Eur J Surg Oncol 2002; 28: 623-5.
- Cserni G: Sentinel lymph-node biopsy-based
prediction of further breast cancer metastases in the
axilla. Eur J Surg Oncol 2001; 27: 532-8.
- Fougo JL, Afonso M, Senhorães Senra F. Predictive
factors for non-sentinel lymph node involvement in
breast cancer patients with a positive sentinel node:
should we consider sentinel node-related factors? Clin
Transl Oncol 2009; 11: 165-71.
- Meretoja TJ, Strien L, Heikkilä PS, et al. A Simple
Nomogram to Evaluate the Risk of Nonsentinel Node
Metastases in Breast Cancer Patients with Minimal
Sentinel Node Involvement. Ann Surg Oncol 2011; 27:
112-7.
- Langer I, Marti WR, Guller U, et al. Axillary recurence
rate in breast cancer patients with negative sentinel
lymph node(SLN) or SLN micrometastases: prospective
analysis of 150 patients after SLN biopsy. Ann Surg
2005; 241: 152-8.
- Chagpar A, Middleton LP, Saghin AA, et al. Clinical
outcome of patients with lymph node-negative breast
carcinoma who have sentinel lymph node
micrometastases detected by immunohistochemistry.
Cancer 2005; 103: 1581-6.
- Giuliano AE, Hunt KK, Ballman KV, et al. Axillary
dissection vs no axillary dissection in women with
invasive breast cancer and sentinel node metastasis: a
randomized clinical trial. JAMA 2011; 305: 569-75.
- Lambert L, Hunt KK, Hwang RF, et al. Validation of a
breast cancer nomogram for predicting additional
nodal metastases after positive sentinel node biopsy.
Ann Surg Oncol 2005; 12: 17-21.
- Soni NK, Carmalt HL, Gillette DJ, et al. Evaluation of a
breast cancer nomogram for prediction of nonsentinel
lymph node positivity. Eur J Sur Oncol 2005; 9: 958-64.
- Degnim A, Reynolds C, Newman LA, et al. Nonsentinel
node metastasis in breast cancer patients: assessment
of an existing and a new predictive nomogram. Am J
Surg 2005; 190: 543–50.
- Smidt ML, Kuster M, Strobbe LJA, et al. Can the
Memorial Sloan-Hettering Cancer Center nomogram
predict the likelihood of nonsentinel lymph node
metastases in breast cancer patients in the
Netherlands? Ann Surg Oncol 2005; 12: 1066-72.
- Arlan S, De Rycke Y, Fourchotte V, et al. Validation
and limitations of use of a breast cancer nomogram
predicting the likelihood of non-sentinel node
involvement after positive sentinel node biopsy. Ann
Surg Oncol 2007; 14: 2195-201.
- Kocsis L, Svebis M, Cserni G, et al. Use and limitations
of a nomogram predicting the likelihood of nonsentinel
node involvement after a positive sentinel
node biopsy in breast cancer patients. Am Surg 2004;
70: 1019-24.
- Klar M, Jochmann A, Foeldi M, et al. The MSKCC
nomogram for prediction the likelihood of non-sentinel
node involvement in a German breast cancer
population. Breast Cancer Res Treat 2008; 112: 523-31
- Gür AS, Ünal B, Johnson R, et al. The predictive
probability of different breast cancer Nomograms for
non sentinel axillary lymph node metastasis in Positive
sentinel lymph node biopsy. Meme Sağlığı Dergisi
2008:4:169-73.
- Hessman CJ, Naik AM, Kearney NM,et al. Comparative
validation of online nomograms for predicting
nonsentinel lymph node status in sentinel lymph nodepositive
breast cancer. Arch Surg 2011; 146: 1035-40.
- Moghaddam Y, Falzon M, Fulford L, et al. Comparison
of three mathematical models for predicting the risk of
additional axillary nodal metastases after positive
sentinel lymph node biopsy in early breast cancer. Br J
Surg 2010; 97: 1646-52.
- Hidar S, Harrabi I, Benregaya L,et al. Validation of
nomograms to predict the risk of non-sentinels lymph
node metastases in North African Tunisian breast
cancer patients with sentinel node involvement. Breast
2011; 20: 26-30.